Academic Journals Database
Disseminating quality controlled scientific knowledge

Sukcesy i porażki badań nad neuroprotekcją w udarze niedokrwiennym mózgu

Author(s): Anna Członkowska | Dagmara Mirowska-Guzel | Andrzej Członkowski

Journal: Neuropsychiatria i Neuropsychologia
ISSN 1896-6764

Volume: 2;
Issue: 2;
Start page: 66;
Date: 2007;
Original page

Keywords: ischemic stroke | experimental studies | clinical trials | neuroprotection

and neurological disability in adult population. Largeprogress was made by introducing recombinant tissueactivator (rt-PA) but according to very strict inclusioncriteria, its use is limited to small number of patients.Effective, well-tolerated treatments are needed todecrease disability and improve patients’ prognosis. Theidea of neuroprotective agent is that it interferes withmechanisms involved in ischemic cascade. Fine resultsobtained with neuroprotectants in models of ischemiaare not reproducible in clinical trials. To improve qualityof experimental studies, STAIR (Stroke Therapy AcademicIndustry Roundtable) introduced recommendationsfor preclinical drug testing. NXY-059 was the only drugwhich fulfilled the STAIR recommendation and muchwas expected with its use. However the results of large,randomized clinical trials were very disappointed and uptill now no neuroprotective drug has been introduced tothe market.

Tango Rapperswil
Tango Rapperswil

     Save time & money - Smart Internet Solutions